S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
NYSE:EHAB

Enhabit (EHAB) Stock Price, News & Analysis

$11.65
+0.09 (+0.78%)
(As of 03/28/2024 ET)
Today's Range
$11.51
$11.74
50-Day Range
$7.81
$11.65
52-Week Range
$7.12
$14.59
Volume
517,451 shs
Average Volume
932,761 shs
Market Capitalization
$584.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.08

Enhabit MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.86 Rating Score
Upside/​Downside
3.7% Upside
$12.08 Price Target
Short Interest
Healthy
9.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.17mentions of Enhabit in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
25.00%
From $0.24 to $0.30 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.77 out of 5 stars

Medical Sector

857th out of 939 stocks

Home Health Care Services Industry

7th out of 8 stocks

EHAB stock logo

About Enhabit Stock (NYSE:EHAB)

Enhabit, Inc. is a leading healthcare provider that offers Medicare-certified skilled home health and hospice services in the United States. The company operates in two segments: Home Health and Hospice, providing services to adult patients needing care, including skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. Enhabit's hospice services include in-home services to terminally ill patients and their families to address patients' physical needs, including pain control and symptom management, and emotional and spiritual support.

Enhabit operates home health agencies in approximately 34 states, with a concentration in the southern half of the United States. As of March 31, 2022, Enhabit operates in 252 home health agencies and 99 hospice agencies across 34 states. Enhabit provides practices to treat chronic diseases and conditions, including diabetes, arthritis, hypertension,  Alzheimer's disease, spinal stenosis, low vision,  Parkinson's disease, complex wound care, osteoporosis, and chronic pain, along with disease-specific plans for patients with diabetes, post-orthopedic surgery or injury, congestive heart failure,  and respiratory diseases.

Enhabit started as HealthSouth, founded in 1984 by Beam Scrushy and Richard Scrushy. In the early 2000s, the company restructured and rebranded into Encompass Health after being caught up in an accounting scandal. In Q2 of 2022, Enhabit, the healthcare and hospice division, became an independent public company, having completed its spinoff from Encompass Health Corporation. 

Barb Jacobsmeyer was named President and CEO of Enhabit Home Health & Hospice in June 2021. Jacobsmeyer came to Enhabit from Encompass Health, where she served as the company's executive vice president of operations. 

In Q3 of 2022, Enhabit, Inc. announced the acquisition of Caring Hearts Hospice, a locally-owned hospice agency in Texas. The acquisition adds four hospice locations in Texas to Enhabit's existing presence in the state. Ehnabit continues to expand, setting aside approximately one hundred million dollars to fund future mergers and acquisitions. 

Enhabit, Inc. is committed to providing high-quality care and service to patients and their families, and its success is a testament to its dedicated team of healthcare professionals. Enhabit is well-positioned to meet the growing demand for healthcare services in the United States as a leading home health and hospice service provider. With its focus on patient care and commitment to excellence, Enhabit is poised to continue to grow and succeed in the years ahead.

Enhabit's commitment to quality care has not gone unnoticed, as they have received numerous awards and recognitions for their services. In 2021, they were named a HomeCare Elite Top Agency for the 15th year. This recognition is given to the top-performing home health agencies in the United States. They have also received a 5-star rating from the Centers for Medicare & Medicaid Services (CMS) for their home health services, indicating their high quality and patient satisfaction.

Enhabit's success can be attributed to its skilled and compassionate staff and dedication to providing comprehensive and individualized patient care. Enhabit also recognizes the importance of emotional and spiritual support for their patients and their families, particularly in hospice care. Their hospice services include pain and symptom management, spiritual counseling, palliative and dietary counseling, social worker visits, and bereavement counseling services to meet terminally ill patients and their families' individual physical, spiritual, emotional, and psychosocial needs.

EHAB Stock Price History

EHAB Stock News Headlines

Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Breaking Down Enhabit: 3 Analysts Share Their Views
Recap: Enhabit Q4 Earnings
Enhabit, Inc. (NYSE:EHAB) Q3 2023 Earnings Call Transcript
See More Headlines
Receive EHAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enhabit and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2024
Today
3/29/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Home health care services
Sub-Industry
N/A
Fax
N/A
Employees
10,800
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.08
High Stock Price Target
$15.00
Low Stock Price Target
$9.50
Potential Upside/Downside
+3.7%
Consensus Rating
Reduce
Rating Score (0-4)
1.86
Research Coverage
7 Analysts

Profitability

Net Income
$-80,500,000.00
Pretax Margin
-8.64%

Debt

Sales & Book Value

Annual Sales
$1.05 billion
Cash Flow
$2.67 per share
Book Value
$13.90 per share

Miscellaneous

Free Float
49,203,000
Market Cap
$584.32 million
Optionable
Optionable
Beta
1.86
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Ms. Barbara Ann Jacobsmeyer B.S. (Age 57)
    M.A., P.T., President, CEO & Director
    Comp: $1.26M
  • Ms. Crissy Buchanan Carlisle (Age 51)
    Executive VP & CFO
    Comp: $611.66k
  • Ms. Tanya R. Marion (Age 49)
    Chief Human Resources Officer
    Comp: $445.86k
  • Ms. Julie Diane Jolley B.S.N. (Age 51)
    R.N., Executive Vice President of Home Health & Hospice Operations
    Comp: $642.65k
  • Ms. Jeanne Kalvaitis B.S.N. (Age 66)
    R.N., Executive Vice President of Hospice Operations
    Comp: $288.38k
  • Mark Brewer
    Chief Investor Relations Officer
  • Mr. Dylan C. Black (Age 54)
    General Counsel & Secretary
  • Mr. Ronald L. Langham Jr. (Age 46)
    M.B.A., P.T., Executive Vice President of Clinical Excellence & Strategy

EHAB Stock Analysis - Frequently Asked Questions

Should I buy or sell Enhabit stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enhabit in the last year. There are currently 2 sell ratings, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" EHAB shares.
View EHAB analyst ratings
or view top-rated stocks.

What is Enhabit's stock price target for 2024?

7 analysts have issued 12 month target prices for Enhabit's stock. Their EHAB share price targets range from $9.50 to $15.00. On average, they anticipate the company's stock price to reach $12.08 in the next twelve months. This suggests a possible upside of 3.7% from the stock's current price.
View analysts price targets for EHAB
or view top-rated stocks among Wall Street analysts.

How have EHAB shares performed in 2024?

Enhabit's stock was trading at $10.35 at the beginning of the year. Since then, EHAB stock has increased by 12.6% and is now trading at $11.65.
View the best growth stocks for 2024 here
.

Are investors shorting Enhabit?

Enhabit saw a decrease in short interest in March. As of March 15th, there was short interest totaling 4,230,000 shares, a decrease of 17.7% from the February 29th total of 5,140,000 shares. Based on an average trading volume of 612,600 shares, the days-to-cover ratio is currently 6.9 days. Currently, 9.6% of the shares of the company are short sold.
View Enhabit's Short Interest
.

When is Enhabit's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our EHAB earnings forecast
.

How were Enhabit's earnings last quarter?

Enhabit, Inc. (NYSE:EHAB) posted its quarterly earnings data on Wednesday, March, 6th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.01. The business had revenue of $260.60 million for the quarter, compared to the consensus estimate of $260.30 million. Enhabit had a negative net margin of 7.69% and a positive trailing twelve-month return on equity of 1.55%. During the same period in the prior year, the firm posted $0.32 earnings per share.

What guidance has Enhabit issued on next quarter's earnings?

Enhabit updated its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share (EPS) guidance of 0.120-0.430 for the period, compared to the consensus estimate of 0.220. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Who are Enhabit's major shareholders?

Enhabit's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.38%), Vanguard Group Inc. (11.38%), Van Lanschot Kempen Investment Management N.V. (4.40%), Paradice Investment Management LLC (4.00%), Dimensional Fund Advisors LP (3.72%) and UBS Group AG (3.32%). Insiders that own company stock include Barbara Ann Jacobsmeyer, Charles M Elson, Erin Hoeflinger, Gregory S Rush, Jeffrey Bolton, John E D D S Maupin Jr, L Edward Shaw Jr, Leo I Higdon Jr, Ronald Leroy Langham Jr and Tanya Renee Marion.
View institutional ownership trends
.

How do I buy shares of Enhabit?

Shares of EHAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:EHAB) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners